Background: Short and ultra-short implants implants supporting single crowns seem to demonstrate high percentages of survival and stable marginal bone levels at a mid-term follow-up. Nevertheless, insurgence of peri-implant complications still represents a critical issue, especially for patients with history of periodontitis.
Purpose: The aim of this retrospective study was to evaluate implant survival, marginal bone loss and peri-implant complications in 333 short and ultra-short implants, placed in periodontally healthy patients and patients with a history of periodontitis.
Materials And Methods: Implants were placed in the maxillary and mandibular posterior regions of 142 patients with (PP) and without (NPP) a history of periodontitis. Clinical and radiographic examinations were performed at 5-year recall appointments.
Results: Implants respectively placed in PP and NPP were: 35.68% and 42.50% in 8.0 mm-length group, 33.33% and 36.67% in 6.0 mm-length group, and 30.99% and 20.83% in 5.0 mm-length group. Implant-based survival after 5 years of follow-up was 95.77% for PP and 96.67% for NPP (p = 0.77). Regarding crestal bone level variations, average crestal bone loss was statistically different (p = 0.04) among PP (0.74 mm) and NPP (0.61 mm). Implants presenting signs of mucositis were 6.86% in PP and 7.76% in NPP (p = 0.76). Setting the threshold for excessive bone loss at 1 mm after 60 months, peri-implantitis prevalence was 7.84% in PP and 2.59% in NPP (p = 0.08). Overall implant success was 92.16% and 97.41%, respectively, for PP and NPP.
Conclusions: Under strict maintenance program, five-year outcomes suggest that short and ultra-short locking-taper implants can be successfully restored with single crowns in the posterior jaws both in PP and NPP.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546440 | PMC |
http://dx.doi.org/10.1111/cid.13103 | DOI Listing |
Proc IEEE Int Symp Biomed Imaging
May 2024
Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA.
Utilizing a multi-task deep learning framework, this study generated synthetic CT (sCT) images from a limited dataset of Ultrashort echo time (UTE) MRI for transcranial focused ultrasound (tFUS) planning. A 3D Transformer U-Net was employed to produce sCT images that closely replicated actual CT scans, demonstrated by an average Dice coefficient of 0.868 for morphological accuracy.
View Article and Find Full Text PDFJ Clin Anesth
February 2025
Monash Health School of Clinical Sciences, Monash University, Melbourne, Australia.
Background: Remimazolam, an ultra-short-acting benzodiazepine, has similar clinical effects to propofol for sedation in general anaesthesia. However, it remains uncertain whether remimazolam could increase postoperative delirium (POD) compared with propofol.
Objectives: The purpose of our study was to compare the incidence of POD between remimazolam and propofol as sedative agents in general anaesthesia.
Physiol Rep
January 2025
Faculty of Health Science and Medicine, Bond University, Robina, Queensland, Australia.
Police officers are exposed to high levels of stress. Serving on Special Weapons and Tactics (SWAT) teams is a highly demanding duty that may further increase levels of stress in police personnel. This stress may accumulate, thereby increasing allostatic load.
View Article and Find Full Text PDFDEN Open
April 2025
Department of Anesthesiology, Fujimoto General Hospital Miyazaki Japan.
Objectives: In gastroenterology, sedation demand is increasing, although elderly patients are more prone to experiencing adverse events. Remimazolam, a novel ultra-short-acting benzodiazepine, may reduce recovery time after endoscopic procedures.
Methods: This study was a secondary analysis of the investigator-initiated trial, which investigated the efficacy and safety of remimazolam in gastrointestinal endoscopy (REM-IICT JP01).
Cureus
January 2025
Anesthesiology and Pain and Palliative Medicine, Radboud University Medical Center, Nijmegen, NLD.
When a difficult airway is anticipated, awake tracheal intubation can be considered. Usually, low doses of sedatives are administered during this procedure for minimal sedation and anxiolysis, such as midazolam and remifentanil. The newly developed ultra-short-acting benzodiazepine remimazolam has a pharmacokinetic profile that is more suitable for titration during awake tracheal intubation than the long-acting midazolam.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!